| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-05-14 | MRC Technology (UK) Daiichi Sankyo (Japan) | drug targets | R&D collaboration |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases | R&D agreement | |
| 2014-05-14 | Hemispherx Biopharma (USA - PA) Swiss Department of Defense, Civil Protection and Sports (Switzerland) | Alferon N Injection® | infection by wild type and Tamiflu® (oseltamivir)-resistant H7N9 influenza virus | Infectious diseases | Establishment of a new subsidiary in the EU | |
| 2014-05-13 | Servier (France) Novartis (Switzerland) | BCL-2 selective inhibitor candidates | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2014-05-13 | DBV Technologies (France) Children’s Hospital of Philadelphia (USA - PA) | Viaskin® Milk | milk-induced eosinophilic esophagitis | clinical research |
Allergic diseases - Inflammatory diseases - Digestive diseases | Clinical research agreement |
| 2014-05-13 | MDxHealth (Belgium) American Pathology Partners (USA - CO) | ConfirmMDx for Prostate Cancer | prostate cancer | commercialisation |
Diagnostic - Cancer - Oncology | Commercialisation agreement |
| 2014-05-13 | Orion Corporation (Finland) Jubilant Biosys (India) | small molecule inhibitors in pain management therapy | pain | development |
CNS diseases | Development agreement |
| 2014-05-12 | AC Immune (Switzerland) Piramal Imaging (India) | Tau protein diagnostics in Alzheimer’s disease | Alzheimer’s disease | R&D development licenisng commercialisation |
Neurodegenerative diseases | Licensing agreement |
| 2014-05-09 | Biogen Idec (USA - MA) Eisai (Japan) | E2609, BAN2401, BIIB037 | Alzheimer’s disease | development |
Neurodegenerative diseases | Development agreement |
| 2014-05-09 | Pfizer (USA - NY) Global Medical Excellence Cluster - GMEC (UK) | collaboration |
Rare diseases | Collaboration agreement | ||
| 2014-05-08 | Horizon Discovery (UK) ERS Genomics (Ireland) | intellectual property (IP) relating to the CRISPR/Cas9 gene editing system | Technology - Services | Licensing agreement | ||
| 2014-05-07 | Oxford BioTherapeutics (UK) Amgen (USA - CA) Immunogen (USA - MA) | Xenomouse® Antibodies and maytansinoid ADC technology for an undisclosed target in HER2-negative breast cancer | HER2-negative breast cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-05-07 | Unilabs (Denmark) BGI (China) | genetics services | collaboration |
Diagnostic - Technology - Services | Collaboration agreement | |
| 2014-05-07 | Grunenthal (Germany) Merck&Co (USA - NJ) | Arcoxia® (etoricoxib) | symptomatic relief of osteoarthritis, rheumatoid arthritis, pain and signs of inflammation associated with acute gouty arthritis | distribution |
Autoimmune diseases – CNS diseases - Inflammatory diseases - Rheumatic diseases | Distribution agreement |
| 2014-05-06 | Evotec (Germany) Eternygen (Germany) | small molecule inhibitors against sodium coupled citrate transporter NaCT to treat metabolic diseases | collaboration |
Metabolic diseases | Collaboration agreement | |
| 2014-05-06 | Synthon (The Netherlands) MAB Discovery (Germany) | antibodies for targets selected by Synthon | R&D licensing |
Technology - Services | R&D agreement | |
| 2014-05-06 | Debiopharm (Switzerland) Yale University (USA - CT) | MIF (Macrophage Migration Inhibitory Factor) inhibitors | R&D licensing |
Autoimmune diseases - Inflammatory diseases | Licensing agreement | |
| 2014-05-06 | Gensight Biologics (France) | chief operating officer | nomination | Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | |
| 2014-05-05 | Cenix Bioscience (Germany) Bayer (Germany) | target discovery project | undisclosed | services |
undisclosed | Services contract |
| 2014-04-30 | Genzyme (USA - MA), a Sanofi company (France) - Cleveland Clinic (USA - OH) | multiple sclerosis | Autoimmune diseases - Neurodegenerative diseases | R&D agreement | ||
| 2014-04-30 | Lundbeck (Denmark) Nanomerics (UK) University College London UCL (UK) Exeter University (UK) | antibody medicines active in the brain | dementia, brain cancer | Cancer - Oncology - Mental diseases - Neurodegenerative diseases - Neurological diseases | Collaboration agreement |
